skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)

(2112) Views  (472) Full article downloads

Authors: Angelo J Cambio, Christopher P Evans

Published Date February 2007 Volume 2007:3(1) Pages 181 - 196
DOI: http://dx.doi.org/10.2147/TCRM.S

Angelo J Cambio, Christopher P Evans

Department of Urology [A.J.C., C.P.E.], University of California, Davis, Sacramento, CA, USA

Background: Benign prostatic hyperplasia (BPH) is a common disease of the aging male population. BPH treatment includes a variety of pharmacological and surgical interventions. The goal of this paper is to review the natural history of BPH, outcomes of pharmacological management, effects on quality of life (QoL), future pharmacotherapies, and associated patient-focused perspectives.

Materials and methods: Medline searches for the keywords benign prostatic hyperplasia, BPH, alpha blockers, 5 alpha-reductase, and quality of life were performed. Relevant literature was reviewed and analyzed.

Results: Alpha blockers, 5 alpha-reductase inhibitors, and phytotherapy are the three categories of pharmaceutical interventions currently available for BPH. Various clinical trials have shown that alpha blockers and 5 alpha-reductase inhibitors are safe, efficacious, and improve QoL in patients with BPH. The evidence for phytotherapeutics is not as convincing. The current armamentarium of pharmaceutical interventions are encompassed in these three classes of medications. New pharmacotherapies based on novel mechanisms are on the horizon.

Conclusion: There are a variety of safe and efficacious medical therapies available for the management of BPH and it is important for the practicing physician to have an understanding of these pharmacotherapies and their potential impact on the patient. There is not enough evidence to make a recommendation regarding phytotherapy use. New classes of drugs for BPH will likely find their way into routine use.

Keywords: Benign prostatic hyperplasia, benign prostatic hypertrophy, BPH, alpha blockers, 5 alpha-reductase inhibitor, quality of life.








Readers of this article also read:

Hypokalemia secondary to capecitabine: a hidden toxicity?
Long-term management of gastroesophageal reflux disease with pantoprazole
Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom
The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
Tramadol extended-release in the management of chronic pain
A review and empirical study of the composite scales of the Das–Naglieri cognitive assessment system
Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment
Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program
Sipuleucel-T: immunotherapy for advanced prostate cancer
Affective psychotherapy in post-traumatic reactions guided by affective neuroscience: memory reconsolidation and play